A mouse model of 22q11.2 deletions

Molecular and behavioral signatures of Parkinson’s disease and schizophrenia

Akiko Sumitomo, Kouta Horike, Kazuko Hirai, Nancy Butcher, Erik Boot, Takeshi Sakurai, Frederick Nucifora, Anne S. Bassett, Akira Sawa, Toshifumi Tomoda

Research output: Contribution to journalArticle

Abstract

Individuals with chromosome 22q11.2 deletions are at increased risk of developing psychiatric conditions, most notably, schizophrenia (SZ). Recently, clinical studies have also implicated these recurrent 22q11.2 deletions with the risk of early-onset Parkinson’s disease (PD). Thus far, the multiple mouse models generated for 22q11.2 deletions have been studied primarily in the context of congenital cardiac, neurodevelopmental, and psychotic disorders. One of these is the Df1/+ model, in which SZ-associated and developmental abnormalities have been reported. We present the first evidence that the mouse model for the 22q11.2 deletion exhibits motor coordination deficits and molecular signatures (that is, elevated -synuclein expression) relevant to PD. Reducing the -synuclein gene dosage in Df1/+ mice ameliorated the motor deficits. Thus, this model of the 22q11.2 deletion shows signatures of both SZ and PD at the molecular and behavioral levels. In addition, both SZ-associated and PD-relevant deficits in the model were ameliorated by treatment with a rapamycin analog, CCI-779. We now posit the utility of 22q11.2 deletion mouse models in investigating the mechanisms of SZ- and PD-associated manifestations that could shed light on possible common pathways of these neuropsychiatric disorders.

Original languageEnglish (US)
Article numbereaar6637
JournalScience advances
Volume4
Issue number8
DOIs
StatePublished - Aug 15 2018

Fingerprint

Parkinson Disease
Schizophrenia
Synucleins
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Chromosome Deletion
Gene Dosage
Sirolimus
Psychotic Disorders
Psychiatry

ASJC Scopus subject areas

  • General

Cite this

Sumitomo, A., Horike, K., Hirai, K., Butcher, N., Boot, E., Sakurai, T., ... Tomoda, T. (2018). A mouse model of 22q11.2 deletions: Molecular and behavioral signatures of Parkinson’s disease and schizophrenia. Science advances, 4(8), [eaar6637]. https://doi.org/10.1126/sciadv.aar6637

A mouse model of 22q11.2 deletions : Molecular and behavioral signatures of Parkinson’s disease and schizophrenia. / Sumitomo, Akiko; Horike, Kouta; Hirai, Kazuko; Butcher, Nancy; Boot, Erik; Sakurai, Takeshi; Nucifora, Frederick; Bassett, Anne S.; Sawa, Akira; Tomoda, Toshifumi.

In: Science advances, Vol. 4, No. 8, eaar6637, 15.08.2018.

Research output: Contribution to journalArticle

Sumitomo, A, Horike, K, Hirai, K, Butcher, N, Boot, E, Sakurai, T, Nucifora, F, Bassett, AS, Sawa, A & Tomoda, T 2018, 'A mouse model of 22q11.2 deletions: Molecular and behavioral signatures of Parkinson’s disease and schizophrenia', Science advances, vol. 4, no. 8, eaar6637. https://doi.org/10.1126/sciadv.aar6637
Sumitomo, Akiko ; Horike, Kouta ; Hirai, Kazuko ; Butcher, Nancy ; Boot, Erik ; Sakurai, Takeshi ; Nucifora, Frederick ; Bassett, Anne S. ; Sawa, Akira ; Tomoda, Toshifumi. / A mouse model of 22q11.2 deletions : Molecular and behavioral signatures of Parkinson’s disease and schizophrenia. In: Science advances. 2018 ; Vol. 4, No. 8.
@article{bf7b70f7fb7a4d87b21e6e9cbe13879d,
title = "A mouse model of 22q11.2 deletions: Molecular and behavioral signatures of Parkinson’s disease and schizophrenia",
abstract = "Individuals with chromosome 22q11.2 deletions are at increased risk of developing psychiatric conditions, most notably, schizophrenia (SZ). Recently, clinical studies have also implicated these recurrent 22q11.2 deletions with the risk of early-onset Parkinson’s disease (PD). Thus far, the multiple mouse models generated for 22q11.2 deletions have been studied primarily in the context of congenital cardiac, neurodevelopmental, and psychotic disorders. One of these is the Df1/+ model, in which SZ-associated and developmental abnormalities have been reported. We present the first evidence that the mouse model for the 22q11.2 deletion exhibits motor coordination deficits and molecular signatures (that is, elevated -synuclein expression) relevant to PD. Reducing the -synuclein gene dosage in Df1/+ mice ameliorated the motor deficits. Thus, this model of the 22q11.2 deletion shows signatures of both SZ and PD at the molecular and behavioral levels. In addition, both SZ-associated and PD-relevant deficits in the model were ameliorated by treatment with a rapamycin analog, CCI-779. We now posit the utility of 22q11.2 deletion mouse models in investigating the mechanisms of SZ- and PD-associated manifestations that could shed light on possible common pathways of these neuropsychiatric disorders.",
author = "Akiko Sumitomo and Kouta Horike and Kazuko Hirai and Nancy Butcher and Erik Boot and Takeshi Sakurai and Frederick Nucifora and Bassett, {Anne S.} and Akira Sawa and Toshifumi Tomoda",
year = "2018",
month = "8",
day = "15",
doi = "10.1126/sciadv.aar6637",
language = "English (US)",
volume = "4",
journal = "Science advances",
issn = "2375-2548",
publisher = "American Association for the Advancement of Science",
number = "8",

}

TY - JOUR

T1 - A mouse model of 22q11.2 deletions

T2 - Molecular and behavioral signatures of Parkinson’s disease and schizophrenia

AU - Sumitomo, Akiko

AU - Horike, Kouta

AU - Hirai, Kazuko

AU - Butcher, Nancy

AU - Boot, Erik

AU - Sakurai, Takeshi

AU - Nucifora, Frederick

AU - Bassett, Anne S.

AU - Sawa, Akira

AU - Tomoda, Toshifumi

PY - 2018/8/15

Y1 - 2018/8/15

N2 - Individuals with chromosome 22q11.2 deletions are at increased risk of developing psychiatric conditions, most notably, schizophrenia (SZ). Recently, clinical studies have also implicated these recurrent 22q11.2 deletions with the risk of early-onset Parkinson’s disease (PD). Thus far, the multiple mouse models generated for 22q11.2 deletions have been studied primarily in the context of congenital cardiac, neurodevelopmental, and psychotic disorders. One of these is the Df1/+ model, in which SZ-associated and developmental abnormalities have been reported. We present the first evidence that the mouse model for the 22q11.2 deletion exhibits motor coordination deficits and molecular signatures (that is, elevated -synuclein expression) relevant to PD. Reducing the -synuclein gene dosage in Df1/+ mice ameliorated the motor deficits. Thus, this model of the 22q11.2 deletion shows signatures of both SZ and PD at the molecular and behavioral levels. In addition, both SZ-associated and PD-relevant deficits in the model were ameliorated by treatment with a rapamycin analog, CCI-779. We now posit the utility of 22q11.2 deletion mouse models in investigating the mechanisms of SZ- and PD-associated manifestations that could shed light on possible common pathways of these neuropsychiatric disorders.

AB - Individuals with chromosome 22q11.2 deletions are at increased risk of developing psychiatric conditions, most notably, schizophrenia (SZ). Recently, clinical studies have also implicated these recurrent 22q11.2 deletions with the risk of early-onset Parkinson’s disease (PD). Thus far, the multiple mouse models generated for 22q11.2 deletions have been studied primarily in the context of congenital cardiac, neurodevelopmental, and psychotic disorders. One of these is the Df1/+ model, in which SZ-associated and developmental abnormalities have been reported. We present the first evidence that the mouse model for the 22q11.2 deletion exhibits motor coordination deficits and molecular signatures (that is, elevated -synuclein expression) relevant to PD. Reducing the -synuclein gene dosage in Df1/+ mice ameliorated the motor deficits. Thus, this model of the 22q11.2 deletion shows signatures of both SZ and PD at the molecular and behavioral levels. In addition, both SZ-associated and PD-relevant deficits in the model were ameliorated by treatment with a rapamycin analog, CCI-779. We now posit the utility of 22q11.2 deletion mouse models in investigating the mechanisms of SZ- and PD-associated manifestations that could shed light on possible common pathways of these neuropsychiatric disorders.

UR - http://www.scopus.com/inward/record.url?scp=85052213018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052213018&partnerID=8YFLogxK

U2 - 10.1126/sciadv.aar6637

DO - 10.1126/sciadv.aar6637

M3 - Article

VL - 4

JO - Science advances

JF - Science advances

SN - 2375-2548

IS - 8

M1 - eaar6637

ER -